According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields
Iridex Corp today announced the award of the European Patent EP 3009093, titled "Laser System with Short Pulse Characteristics and its Methods of Use.”
According to a news release from the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilise the patented technology.1
"This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorised provider of MicroPulse technology," David Bruce, president and CEO of Iridex, said in the news release.
According to the company, the technology delivers a laser system capability for delivering short, controlled-width pulse trains designed to minimise the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond.
Moreover, by employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.1
The company also pointed out that its MicroPulse technology also incorporates software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The technology covers the full laser wavelength range from 520 nm to 615 nm.
According to the news release the Unitary Patent will be enforced in European countries by members of the Unified Patent Court as well as the United Kingdom.